Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to
cancer cells while minimizing systemic toxic effects and may lead to additional treatment …

Background Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone
metastases with alpha particles. We assessed the efficacy and safety of radium-223 as …

Background Primary results from the phase 3 ALSYMPCA trial showed that radium-223
dichloride (radium-223), a targeted α-emitter, improved overall survival compared with …

Background Bone metastases frequently cause skeletal events in patients with metastatic
castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets …

Which elements are essential for human life? Here we make an element-by-element journey
through the periodic table and attempt to assess whether elements are essential or not, and …

Bone is the most common site of metastasis for breast cancer. Bone metastasis significantly
affects both quality of life and survival of the breast cancer patient. Clinically, complications …

This review presents an overview of the successes and challenges currently faced in alpha
radionuclide therapy. Alpha particles have an advantage in killing tumour cells as compared …

Background The alpha-emitter radium-223 (223 Ra) is a bone-seeking radionuclide studied
as a new treatment for patients with bone metastases from hormone-refractory prostate …

Purpose: The main goals were to study the safety and tolerability of the α-emitter radium-223
(223Ra) in breast and prostate cancer patients with skeletal metastases. In addition, pain …